Novaliq receives FDA nod for Vevye Vevye (cyclosporine ophthalmic solution) 0.1% is used for the treatment of the signs and symptoms of dry eye disease. Sandoz obtains FDA nod for first Tysabri biosimilarTyruko is the first biosimilar to Tysabri injection for the treatment of adults with relapsing forms of multiple sclerosis. CMP Pharma debuts Liqrev Liqrev is indicated for the treatment of pulmonary arterial hypertension in adults to improve exercise ability and delay clinical worsening. Camber launches generic Zetia Ezetimibe tablets are an inhibitor of intestinal cholesterol (and related phytosterol) absorption indicated as an adjunct to diet. Roche obtains FDA nod for Columvi Roche’s Columvi is the first and only bispecific antibody with a fixed-duration treatment for people with relapsed or refractory diffuse large B-cell lymphoma. FDA approves first oral antiviral for treatment of COVID-19 in adults Pfizer's Paxlovid is the first oral antiviral pill approved by the FDA to treat COVID-19 in adults. Mallinckrodt to file for Chapter 11 bankruptcy again Mallinckrodt expects to complete the contemplated prepackaged Chapter 11 process in the fourth quarter of 2023. Gilead gets FDA nod for new indication for Veklury Veklury is the only approved COVID-19 antiviral treatment across all stages of liver disease. CVS Health launches Cordavis As its first product, Cordavis has contracted with Sandoz to commercialize and bring to market Hyrimoz, a biosimilar for Humira. FDA OKs new indication for Eli Lilly’s Verzenio High-risk patients eligible for Verzenio can now be identified solely based on nodal status, tumor size and tumor grade, regardless of Ki-67 score. First Previous 76 77 78 79 80 Next Last
